|
카테고리
|
Cytokines & Growth Factor
|
|
CAT.NO
|
LGP-10-165
|
|
PRODUCT
|
OPG, Human (Osteoprotegerin)
|
|
SIZE
|
50ug, 250ug, 1mg
|
|
PRICE
|
KRW 285,000, 760,000, 2,100,000
|
Technical Parameters
| Synonyms |
TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member 11B |
| Species |
9 |
| Accession |
O00300 |
| GeneID |
4982 |
| Source |
Escherichia coli. |
| Molecular Weight |
Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 173 amino acids. |
| Quantity |
50µg/250µg/1000µg |
| AA Sequence |
ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK |
| Purity |
> 95 % by SDS-PAGE and HPLC analyses. |
| Biological Activity |
Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL). |
| Physical Appearance |
Sterile Filtered White lyophilized (freeze-dried) powder. |
| Formulation |
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0. |
| Endotoxin |
Less than 1 EU/μg of rHuOPG as determined by LAL method. |
| Reconstitution |
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions. |
| Stability & Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution. |
| Usage |
This material is offered by Korea Lugen Sci for research, laboratory or further evaluation purposes. NOT FOR HUMAN USE. |
| SDS-PAGE |
 |
| Reference |
1. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Cell. 89:309-19.
2. Schoppet M, Preissner KT, Hofbauer LC. 2002. Arterioscler Thromb Vasc Biol. 22:549-53.
3. Tsuda E, Goto M, Mochizuki S, et al. 1997. Biochem Biophys Res Commun. 234:137-42.
4. Luan X, Lu Q, Jiang Y, et al. 2012. J Immunol. 189:245-52. |
| Background |
Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively. |
|
|
첨부파일
|
|
|
|
|
|
